Effects of the menstrual cycle on injection pain due to rocuronium

J Clin Anesth. 2013 Aug;25(5):399-402. doi: 10.1016/j.jclinane.2013.02.007. Epub 2013 Aug 17.

Abstract

Study objective: To investigate the effect of the menstrual cycle on rocuronium injection pain.

Design: Prospective, randomized, double-blinded study.

Setting: Academic medical center.

Patients: 80 ASA physical status 1 and 2 women scheduled for elective surgery with general anesthesia.

Measurements: Patients were divided into two groups according to their time in the menstrual cycle. Forty patients at days 8 to 12 of the menstrual cycle were considered to be at the follicular phase (Group F), and 40 patients at days 20 to 24 of the menstrual cycle were considered to be at the luteal phase (Group L).Withdrawal movements were recorded.

Main results: Overall frequency of withdrawal movements was significantly higher in Group L than Group F (P < 0.001). The mean withdrawal movement score was 1.77 ± 0.76 in Group L and 0.52 ± 0.67 in Group F.

Conclusion: Menstrual cycle phases affect the severity of rocuronium injection pain. Women exhibit greater pain sensitivity from rocuronium injection in the luteal phase than the follicular phase.

Keywords: Injection pain; Menstrual cycle; Rocuronium.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Academic Medical Centers
  • Adolescent
  • Adult
  • Androstanols / administration & dosage
  • Androstanols / adverse effects*
  • Anesthesia, General / methods
  • Double-Blind Method
  • Elective Surgical Procedures / methods
  • Female
  • Follicular Phase / physiology
  • Humans
  • Injections, Intravenous
  • Luteal Phase / physiology
  • Menstrual Cycle / physiology*
  • Middle Aged
  • Movement / physiology
  • Neuromuscular Nondepolarizing Agents / administration & dosage
  • Neuromuscular Nondepolarizing Agents / adverse effects*
  • Pain / chemically induced*
  • Prospective Studies
  • Rocuronium
  • Severity of Illness Index
  • Young Adult

Substances

  • Androstanols
  • Neuromuscular Nondepolarizing Agents
  • Rocuronium